

MASCC/ISOO 2014 International Symposium

Representatives from Mueller Medical International will attend the MASCC/ISOO 2014 International Symposium in Miami, Florida from June 26 – 28 to raise awareness of ProThelial™ among medical professionals.

ProThelial™ is an FDA-cleared medical device that not only eliminates the symptoms of oral mucositis, but reverses them, cutting short the course to a few days, keeping patients mucositis-free while continuing treatment at a fraction of the cost of traditional treatments.

Dr. Ricky McCullough, a physician and chemist, found that the well-known substance sucralfate, when highly concentrated, polymerized and formed into a paste, would create a protective layer over the oral mucosa by adhering to the mucosal surface, thereby relieving pain and protecting against further irritation.

McCullough formed Mueller Medical International LLC, which tested and received FDA approval in 2013 for ProThelial™ as a medical device that treats or prevents oral mucositis by a mechanical mode of action.

“Mucositis is a stubborn consequence for some patients of cancer treatment therapy,” McCullough said. “There are no interventions that have been able to alter the course of mucositis once it is established; it’s there for 60 to 70 days. Unfortunately the patient suffers and the costs of care soars.

“The active component of Prothelial™ is cross-linked polymerized high potency sucralfate (PCLS). Unlike regular sucralfate, PCLS has been found to maintain high-surface concentrations that result in novel clinical effects, one of which is the ability to alter the course of mucositis.”

Mueller Medical will host a booth at the conference and will have representatives to help answer questions about this breakthrough treatment. The conference, according to the MASCC/ISOO website, has “developed a reputation for providing the most current data and innovative techniques with regards to how best minimize therapy-induced side effects and complications associated with cancer.”

For more information, visit Muller Medical online at www.MuellerMedical.com or call 401-397-6203.

About Mucositis

Mucositis is a painful inflammation of the mucous membrane lining, often involving erythema, erosion and ulcerations that heal poorly and can become secondarily infected by bacteria, viruses or fungi. Mucositis occurs when mucous membranes are injured either by chemotherapy and/or radiation therapy in individuals undergoing cancer treatment. Mucositis most often affects the oral cavity, pharynx and the esophagus, though it may affect the small and large intestine, causing pain, nausea, vomiting, cramping and diarrhea. The condition affects some 400,000 people in the United States and adds some \$15,000 to \$43,000 to the cost of treating a patient with head or neck cancer.

About ProThelial™

ProThelial™ is a device indicated for the management (treatment and prevention) of oral mucositis of any cause. Chemo-radiation treatment for cancer is the most common cause of oral mucositis. ProThelial™ is the first and only FDA-cleared polymerized sucralfate paste commercially available for oral mucositis.

Unlike a drug, a medical device causes no chemical reaction to tissues of the body, rather it treats or prevents disease by a mechanical mode of action. ProThelial™ polymerized Sucralfate Malate Paste forms a protective layer over the oral mucosa by adhering to the mucosal surface which allows it to protect against further irritation and relieve pain. This improved adherence assists the body's existing mechanisms for healing.

The paste is used in the management of mouth lesions of all types including stomatitis and mucositis caused by chemoradiation therapy.

About Mueller Medical

Mueller Medical International is a family run, privately owned life science company focused on turning science into solutions. Founded in 1989 and headquartered in Rhode Island, USA, Mueller Medical has created products whose mechanism of action stabilizes innate mucosal immuno-physiology with unique clinical effects. Therapeutics for direct sales in the United States, Europe, India and worldwide include ProThelial™ for definitive management of chemo-radiation mucositis, Orafate™ for oral surgical wounds and periodontal gingivitis as well as prescription veterinary products for the GI tract. Products discovered through research and development treat IBS, NERD, erosive GERD, ulcerative colitis, viral/bacterial gastroenteritis, fibromyalgia and benign prostatic hypertrophy.